Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556861 | 0.94 | MAPT (0.54) | KDM4EMAPTCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL18549588 | 0.92 | MAPT (0.53) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL4556315 | 0.86 | MAPT (0.47) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL10815 | 0.86 | DRD2 (0.59) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL1246501 | 0.85 | PNMT (0.47) | KDM4EMAPTCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL31432826 | 0.84 | DRD2 (0.57) | KDM4EMAPTCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL31437001 | 0.83 | PNMT (0.46) | KDM4EMAPTCA12CA1CA2 | |
| Methylamine SCHEMBL27630838 | 0.81 | DRD2 (0.53) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL596333 | 0.78 | PNMT (0.48) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL29417773 | 0.78 | PNMT (0.48) | KDM4EMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| WO-2024222814-A1 | CYP11B2 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-10-31 | — | — | WO | disclosed |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4137483-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Zhongze Therapeutics, Co. Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-113527206-B | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-07-14 | — | — | US | disclosed |
| CN-113527206-A | Benzoazaheterocycle compound, preparation method and application thereof | 上海中泽医药科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010151318-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1951676-A2 | LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6716841-B2 | SUCH AS 1-((1-(3-(AMINOMETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL)CARBONYL) -5-(2-( AMINOSULFONYL)PHENYL)-2,3-DIHYDRO-1H-INDOLE FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2003-05-22 | — | — | US | disclosed |
| US-6429205-B1 | ANTICOAGULANTS | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | SERPINC1, CTRB1, F2 | KDM4E 4169/4885MAPT 4431/4885CA12 1420/4885 |
| US-20230159463-A1 | BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HDAC11, HDAC1, HDAC6 | KDM4E 1120/4885MAPT 1867/4885CA12 1546/4885 |
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | KDM4E 1452/4885MAPT 4275/4885CA12 4866/4885 |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | KDM4E 592/4885MAPT 2212/4885CA12 1826/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | KDM4E 2892/4885MAPT 2888/4885CA12 4733/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | KDM4E 2892/4885MAPT 2888/4885CA12 4733/4885 |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | KDM4E 2892/4885MAPT 2888/4885CA12 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.